Evaluation of the Role of Intravitreal Tissue Plasminogen Activator in Treatment of Refractory Diabetic Macular Edema
- Sponsor
- Mashhad University of Medical Sciences
- Study ID
- NCT01141881
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tissue Plasminogen Activator,bevacizumab ,follow up — DRUG25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing
Study Details
Purpose: to evaluate the effect of intravitreal injection of tissue plasminogen activator(tPA) in treatment of refractory diabetic macular edema(DME).
Key Dates
- First listed
- Jun 11, 2010
- Start date
- May 31, 2009
- Status verified
- Sep 2008
- Primary completion
- Jan 31, 2010
- Completion
- Mar 31, 2010
Study Design
- Primary purpose
- TREATMENT
Arms
- Experimental: TPA,IVB,F/U
Related Studies
- Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)PHASE1 · Recruiting · Ocugen · Deerfield Beach, Florida
- EC-104 Intravitreal Implant for the Treatment of Diabetic Macular EdemaPHASE1/PHASE2 · Recruiting · Eclipse Life Sciences, Inc. · Tampa, Florida
- Intranasal Delivery of Octreotide for Treatment of Diabetic Macular EdemaPHASE1 · Not Yet Recruiting · University of Alabama at Birmingham · Birmingham, Alabama
- Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)PHASE2 · Recruiting · Sierra Eye Associates · Reno, Nevada